Editor Profile

Mark V. Dahl, MD

Associate Editor

About the NEJM Journal Watch Dermatology Board

Mark V. Dahl, MD, is currently Professor of Dermatology, College of Medicine, Mayo Clinic, and Senior Consultant in the Department of Dermatology at Mayo Clinic in Scottsdale/Phoenix, Arizona. He has served as President of the American Academy of Dermatology and as Vice President of the Society for Investigative Dermatology. He is the founder of Camp Discovery, a camping program for children with severe skin diseases. Dr. Dahl is a recipient of the Gold Medal, the American Academy of Dermatology's highest honor, and was named a Master Dermatologist by the organization in 2006. His research has focused on immunology, infections, and inflammatory diseases of the skin, including studies related to immunodeficiency, chemotaxis, granuloma annulare, immunofluorescence, bullous diseases, psoriasis, cutaneous irritation, allergy, rosacea, the epidermal acetylcholine network, and cutaneous fungal infections. Dr. Dahl joined the NEJM Journal Watch Dermatology board in 2007 and served until the publication’s closure in 2016.


Consultant / Advisory board

Ulthera, Inc.; AuBio LifeSciences, LLC; Paris Therapeutics


Elorac, Inc.; Makucell, Inc.; Paris Therapeutics

Editorial boards


Leadership positions in professional societies

National Rosacea Society (Chairman, Medical Board)

  • September 22, 2014

    Short-Course Co-Trimoxazole for Impetigo Treatment

    1. Mark V. Dahl, MD

    Oral co-trimoxazole was noninferior to intramuscular benzathine benzylpenicillin for improving or healing lesions in 7 days.

  • August 13, 2014

    Transcriptomes and Atopic Dermatitis

    1. Mark V. Dahl, MD

    A comprehensive analysis discloses some important genes and their protein products.

  • August 13, 2014

    Stemming Hair Loss?

    1. Mark V. Dahl, MD

    Stem cell dormancy was reversed by a nearby macroenvironment of young skin.

  • July 16, 2014

    Nocebo EffectsFree

    1. Mark V. Dahl, MD

    Patients' expectations are important determinants of unwanted adverse effects, and clinicians must be strategic to foster optimal treatment outcomes.

  • July 15, 2014

    Nodulocystic Acne Regimens

    1. Mark V. Dahl, MD

    Is there an effective alternative for patients unwilling or unable to take oral isotretinoin?

  • July 9, 2014

    Secukinumab for Plaque PsoriasisFree

    1. Mark V. Dahl, MD

    PASI, global assessment, and quality-of-life measures all showed efficacy.